At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
California Pacific Medical Center Research Institute·interventional·Posted Dec 1, 2005·Updated Mar 22, 2013
In Brief
A Phase 1 clinical trial evaluating Rituximab for Chronic Focal Encephalitis and Rasmussen's Encephalitis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and effectiveness of rituximab in the treatment of chronic focal encephalitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedDec 2005
Primary CompletionDec 2008
TodayJul 2026
First PostedDec 1, 2005
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 20.6 years ago
Interventions
Rituximabdrug
375 mg/m2 given as an IV infusion once weekly for four doses